Function of microRNA in pro-inflammatory gene expression
Function of microRNA in pro-inflammatory gene expression
批准号:
8008824
负责人:
PETER S TOBIAS
金额:
$45.55万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-01-01 至 2012-12-31
关键词:
3&apos Untranslated RegionsAffectArthritisBindingBinding ProteinsBiochemicalBiologicalBiological ProcessCellsComplexCytokine GeneDataDevelopmentDiseaseDrosophila genusElementsFamilyFamily memberFunctional RNAFutureGene ExpressionGene TargetingGenesGeneticHousekeepingHumanImmune responseImmune systemInfectionInflammationInflammatoryInflammatory Bowel DiseasesInflammatory ResponseInjuryInterleukin-1Interphase CellLifeMediatingMediator of activation proteinMessenger RNAMicroRNAsMolecularMultiple SclerosisPaperPhysiologicalProcessProductionRNARNA-Induced Silencing ComplexRegulationResearchResearch PersonnelRheumatoid ArthritisRoleSepsisSeptic ShockSignal PathwaySmall Interfering RNAStimulusTIS11 proteinTraumaTumor Necrosis Factor-alphaWorkbasecyclooxygenase 2cytokinegenome wide association studygenome-widehuman DICER1 proteininterestmRNA DecaymRNA StabilitymRNA Transcript Degradationmembernovelphrasespreventprogramsresponse
中文摘要
炎症是身体对感染或损伤的自然保护性反应,但不正常或不受控制
炎症反应弊大于利。在适当的监管方面的崩溃
炎症是一系列常见疾病的基础,如类风湿性关节炎、炎症性肠炎
疾病、多发性硬化症和感染性休克。细胞表达促炎基因的研究进展
免疫系统是炎症发展过程中最关键的一步。尽管取得了重大进展
目前,促炎症基因表达的机制仍不完全清楚。长的-
这项建议的术语目标是了解microRNA的调节和功能
(MiRNA)是新近发现的一组短小的非编码单链RNA,在PRO-2的表达中起重要作用。
炎症基因。已知的促炎基因,如肿瘤坏死因子、白介素1和
环氧合酶2在多个基因表达水平上受到控制,其中最重要的一个是
在当时的mRNA稳定性的调节。这些致炎基因的快速RNA降解服务于
作为一种控制促炎分子水平的机制。富Au元素(ARE)位于
这些短暂的mRNAs的3‘非翻译区决定了它们的降解。我们最近的研究表明
DICER和ARGANUTE(AGO/eif2C)家族成员,参与microRNA(MiRNA)加工的组件
和功能,是含有ARE的信使核糖核酸(ARE-mRNAs)快速衰退所必需的。此外,我们
发现miR16,一个具有与ARE序列部分互补的序列的人miRNA,为
是Are-mRNA周转所必需的。MiR16在静息细胞ARE-mRNA衰变中的需求表明
MiR16的一种生理“内务”功能,可防止基础水平较高的促炎因子
基因表达。这项建议概述了对miRNA调节细胞因子基因机制的研究。
表达,重点是炎症刺激如何通过阻断ARE-mRNA而使其稳定
MiRNA介导的mRNA降解。在这个研究计划中,我们还将评估细胞的整体功能
通过对miR16靶基因进行全基因组鉴定和分类。为了实现我们的目标,我们将
综合运用遗传、生物化学和分子生物学方法。中提议的工作
这一应用将有助于更好地理解促炎基因的表达。理解
MiRNA在促炎基因的mRNA稳定性中的作用应为
开发新型消炎药。
英文摘要
Inflammation js the body's natural protective response to infection or injury, but abnormal or uncontrolled
inflammatory responses can do more harm than good. A breakdown in the appropriate regulation of
inflammation underlies a wide range of common diseases, such as rheumatoid arthritis, inflammatory bowel
disease, multiple sclerosis, and septic shock. The expression of pro-inflammatory genes by cells in the
immune system is the most crucial step in the development of inflammation. Although significant progress
has been made, the mechanism of pro-inflammatory gene expression is still not fully understood. The long-
term objective of this proposal is to gain an understanding of the regulation and function of microRNA
(miRNA), a newly identified group of short non-coding single-stranded RNA, in the expression of pro-
inflammatory genes. It is knownthat pro-inflammatory genes such as tumor necrosis factor, interleukin-1, arid
cyclooxygenase 2 are controlled at multiple levels of gene expression, one of the most important of which is
at the regulation of then- mRNAstability. Quick mRNAdegradation of these pro-inflammatorygenes serves
as a mechanism to control the level of pro-inflammatory molecules. AU-rich elements (AREs) located in the
3' untranslated region of these short-lived mRNAs dictate their degradation. Ourrecent study revealed that
Dicer and Argonaute (Ago/eif2C) family members, components involved in microRNA(miRNA) processing
and function, are required for the rapid decay of mRNA that contain AREs (ARE-mRNA). Furthermore, we
found miR16, a human miRNAwith a sequence that is partially complementaryto the ARE sequence, to be
required for ARE-mRNAturnover. The requirement of miR16 in ARE-mRNA decay in resting cells suggests
a physiological 'housekeeping' function of miR16 in which it prevents high basal levels of pro-inflammatory
gene expression. This proposal outlines a study into the mechanism of miRNA-regulated cytokine gene
expression, with an emphasis on how inflammatory stimuli induce stabilization of ARE-mRNA by blocking
miRNA-mediated mRNA degradation. In this research plan, we will also evaluate the overall function of
miR16 by genome-wide identifying and classifying of miR16-targeted genes. To achieve our aims, we will
utilize a combination of genetic, biochemical, and molecular biological approaches. The work proposed in
this application will contribute to a better understanding of pro-inflammatory gene expression. Understanding
the function of miRNA in mRNA stability of pro-inflammatory genes should provide new avenues for
developing novel anti-inflammatoryagents.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
MicroRNAs and cardiovascular diseases.
microRNA和心血管疾病。
DOI:
10.1111/j.1742-4658.2011.08090.x
发表时间:
2011-05
期刊:
The FEBS journal
影响因子:
--
作者:
[Ono K, Kuwabara Y, Han J]
通讯作者:
Han J
Abdominal Adipose Tissue Inflammation
-
批准号:8403782
-
项目类别:
-
资助金额:$22.55万
-
财政年份:2012
-
负责人:PETER S TOBIAS
-
依托单位:
HIGH-THROUGHPUT ASSAYS TO IDENTIFY INHIBITORS OF CARD-CARD INTERACTIONS
-
批准号:7976276
-
项目类别:
-
资助金额:$28.49万
-
财政年份:2010
-
负责人:PETER S TOBIAS
-
依托单位:
High Throughput Screening Assays to Identify Inhibitors of TLR4 Signaling
-
批准号:8050426
-
项目类别:
-
资助金额:$18.99万
-
财政年份:2010
-
负责人:PETER S TOBIAS
-
依托单位:
HIGH-THROUGHPUT ASSAYS TO IDENTIFY INHIBITORS OF CARD-CARD INTERACTIONS
-
批准号:8143279
-
项目类别:
-
资助金额:$23.5万
-
财政年份:2010
-
负责人:PETER S TOBIAS
-
依托单位:
HIGH THROUGHPUT SCREENING FOR TOLL-LIKE RECEPTORS INHIBITORS
-
批准号:7437561
-
项目类别:
-
资助金额:$37.9万
-
财政年份:2008
-
负责人:PETER S TOBIAS
-
依托单位:
HIGH THROUGHPUT SCREENING FOR TOLL-LIKE RECEPTORS INHIBITORS
-
批准号:7568231
-
项目类别:
-
资助金额:$47.38万
-
财政年份:2008
-
负责人:PETER S TOBIAS
-
依托单位:
HIGH THROUGHPUT SCREENING FOR TOLL-LIKE RECEPTORS INHIBITORS
-
批准号:7755427
-
项目类别:
-
资助金额:$46.9万
-
财政年份:2008
-
负责人:PETER S TOBIAS
-
依托单位:
High Throughput Screening for Toll-Like Receptors
-
批准号:7304744
-
项目类别:
-
资助金额:$2.5万
-
财政年份:2007
-
负责人:PETER S TOBIAS
-
依托单位:
TLR Signaling and Protein Fragment Complementation
-
批准号:6758801
-
项目类别:
-
资助金额:$23.46万
-
财政年份:2004
-
负责人:PETER S TOBIAS
-
依托单位:
DEFINING INNATE IMMUNE RECEPTOR LIGAND BINDING SITES
-
批准号:7002685
-
项目类别:
-
资助金额:$52.54万
-
财政年份:2004
-
负责人:PETER S TOBIAS
-
依托单位:
DEFINING INNATE IMMUNE RECEPTOR LIGAND BINDING SITES
-
批准号:6838790
-
项目类别:
-
资助金额:$52.25万
-
财政年份:2004
-
负责人:PETER S TOBIAS
-
依托单位:
DEFINING INNATE IMMUNE RECEPTOR LIGAND BINDING SITES
-
批准号:6733247
-
项目类别:
-
资助金额:$56.59万
-
财政年份:2004
-
负责人:PETER S TOBIAS
-
依托单位:
DEFINING INNATE IMMUNE RECEPTOR LIGAND BINDING SITES
-
批准号:7173735
-
项目类别:
-
资助金额:$52.53万
-
财政年份:2004
-
负责人:PETER S TOBIAS
-
依托单位:
TLR Signaling and Protein Fragment Complementation
-
批准号:6869550
-
项目类别:
-
资助金额:$28.16万
-
财政年份:2004
-
负责人:PETER S TOBIAS
-
依托单位:
PATHOPHYSIOLOGY OF LPS-CD14 COMPLEXES
-
批准号:6564821
-
项目类别:
-
资助金额:$4.09万
-
财政年份:2001
-
负责人:PETER S TOBIAS
-
依托单位:
STRUCTURAL CHARACTERIZATION OF INNATE IMMUNITY RECEPTORS
-
批准号:6387214
-
项目类别:
-
资助金额:$13.3万
-
财政年份:2000
-
负责人:PETER S TOBIAS
-
依托单位:
STRUCTURAL CHARACTERIZATION OF INNATE IMMUNITY RECEPTORS
-
批准号:6166902
-
项目类别:
-
资助金额:$13.3万
-
财政年份:2000
-
负责人:PETER S TOBIAS
-
依托单位:
PATHOPHYSIOLOGY OF LPS-CD14 COMPLEXES
-
批准号:6418792
-
项目类别:
-
资助金额:$4.09万
-
财政年份:2000
-
负责人:PETER S TOBIAS
-
依托单位:
GENETICS OF THE ENDOTOXEMIC PHENOMENON
-
批准号:6307360
-
项目类别:
-
资助金额:$2.74万
-
财政年份:1999
-
负责人:PETER S TOBIAS
-
依托单位:
PATHOPHYSIOLOGY OF LPS-CD14 COMPLEXES
-
批准号:6302125
-
项目类别:
-
资助金额:$14.84万
-
财政年份:1999
-
负责人:PETER S TOBIAS
-
依托单位:
海外基金